Table 2.

Meta-analysis of the association between MDM2 SNP285 polymorphism and cancer risk.

Variables	Number of studies	Heterozygous			Dominant			Allele comparison
		GC versus GG			(CC+GC) versus GG			C versus G
		OR (95% CI)	P het	I 2 (%)	OR (95% CI)	P het	I 2 (%)	OR (95% CI)	P het	I 2 (%)
All1	15	0.89 (0.79–0.99)	0.120	31.2	0.90 (0.79–1.01)	0.043	42.2	0.91 (0.80–1.03)	0.014	50.0
Cancer type
Breast	4	0.81 (0.61–1.08)	0.074	56.8	0.84 (0.61–1.15)	0.033	65.7	0.87 (0.62–1.22)	0.015	71.4
Lung	3	1.07 (0.86–1.34)	0.676	0.0	1.09 (0.87–1.36)	0.726	0.0	1.10 (0.89–1.37)	0.773	0.0
Prostate	2	1.02 (0.84–1.25)	0.664	0.0	1.06 (0.87–1.30)	0.677	0.0	1.10 (0.91–1.34)	0.700	0.0
Ovarian	2	0.77 (0.63–0.94)	0.903	0.0	0.76 (0.63–0.93)	0.943	0.0	0.77 (0.63–0.93)	0.985	0.0
Others2	4	0.86 (0.66–1.11)	0.175	39.5	0.85 (0.64–1.12)	0.122	48.2	0.84 (0.63–1.14)	0.084	54.8
Ethnicity
Caucasian	13	0.88 (0.79–0.98)	0.088	36.9	0.89 (0.79–1.00)	0.028	47.7	0.90 (0.79–1.03)	0.008	55.2
African	1	1.80 (0.36–9.03)	—	—	1.80 (0.36–9.03)	—	—	1.79 (0.36–8.93)	—	—
Mixed	1	1.76 (0.32–9.79)	—	—	1.76 (0.32–9.79)	—	—	1.74 (0.32–9.62)	—	—
Sample size
<500	6	0.79 (0.51–1.21)	0.079	49.4	0.84 (0.52–1.35)	0.030	59.5	0.89 (0.54–1.47)	0.012	65.8
≥500	9	0.92 (0.84–1.00)	0.525	0.0	0.93 (0.85–1.02)	0.368	8.1	0.94 (0.85–1.04)	0.233	23.6

¹Vargas-Torres et al. (2014), it was not calculated for these models because the numbers of GC and CC genotypes were zero.

²The others included endometrial cancer [16], hepatocellular carcinoma [19], colon cancer [21], and cervical cancer [22].